ANIXA BIOSCIENCES, INC. Treasury Stock Acquired, Average Cost Per Share
ANIXA BIOSCIENCES, INC. (ANIX) reported Treasury Stock Acquired, Average Cost Per Share of $3.17 per share for the 3-month period ending 2025-01-31, per its 10-Q filed 2025-03-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:TreasuryStockAcquiredAverageCostPerShare · last filed 2026-09-09
- ANIXA BIOSCIENCES, INC. treasury stock acquired, average cost per share for the quarter ending 2025-01-31 was $3.17.
| Period end | Treasury Stock Acquired, Average Cost Per Share 3 month | Treasury Stock Acquired, Average Cost Per Share 12 month |
|---|---|---|
| 2025-01-31 | $3.17 10-Q · filed 2025-03-11 | |
| 2024-10-31 | $3.17 10-Q · filed 2026-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |